AlzeCure Pharma AB (AC6) Stock Statistics & Valuation Metrics

AlzeCure Pharma AB has a market cap or net worth of €19.77M. The enterprise value is €169.67M.

AlzeCure Pharma AB has 114,914,450 shares outstanding. The number of shares has decreased by -2.65% in one year.

AlzeCure Pharma AB’s return on equity (ROE) is -1.45 and return on invested capital (ROIC) is -139.15%.

The current PE Ratio of AlzeCure Pharma AB is ―. AlzeCure Pharma AB’s PEG ratio is -1.94.

In the last 12 months, AlzeCure Pharma AB had revenue of 0.00 and earned -47.65M in profits. Earnings per share was -0.47.

In the last 12 months, operating cash flow was -34.59M and capital expenditures 0.00, giving a free cash flow of -34.59M billion.

AlzeCure Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

AlzeCure Pharma AB upcoming earnings date is May 5, 2026, TBA (Confirmed).

AlzeCure Pharma AB as a current ratio of 2.33, with Debt / Equity ratio of 15.55%

In the past 12 months, AlzeCure Pharma AB has paid 18.00K in taxes.

AlzeCure Pharma AB EV to EBITDA ratio is -3.24, with an EV/FCF ratio of -4.50.

AlzeCure Pharma AB has €50.34M in cash and marketable securities with €5.12M in debt, giving a net cash position of €45.22M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for AlzeCure Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―